Screener Summaries Updates Institutions Sign In More Updates › Leadership & Pay › ILMN Leadership & Pay · Jun 23, 2026
Illumina, Inc. increased its Board of Directors from nine to ten members by appointing Daniel M. Skovronsky, M.D.… ILMN Illumina, Inc.
Illumina, Inc. increased its Board of Directors from nine to ten members by appointing Daniel M. Skovronsky, M.D., Ph.D., to the Board, effective immediately. Dr. Skovronsky is an independent director who will stand for election at the 2027 annual meeting of stockholders. Illumina, Inc. is a biotechnology company that provides genomic sequencing technology and sequencing-based information.
More from Illumina, Inc. Illumina reports Q3 revenue of $1.13 billion, raises full-year guidance Oct 29, 2026 Illumina establishes $1.0 billion unsecured commercial paper program Oct 13, 2026 On August 17, 2026, Illumina completed a public offering of $300 million aggregate principal amount of its 4.950%… Aug 17, 2026 Illumina, Inc. entered into a new $1,000 million senior unsecured five-year revolving credit facility on August 13… Aug 13, 2026 On August 10, 2026, Illumina entered into an underwriting agreement to issue and sell $300 million in aggregate… Aug 12, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
